Search

Filter Options

Active Development

Reset

Delivery Type

Reset

Duration Type

Reset

Developer

Reset

User

Reset

Hormonal

Reset

Development Stage

Reset

Potential MPT

Reset

API

Reset
View by user and type (hormonal or non-hormonal)
Displaying 51 - 60 of 243
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Concept Foundation, Sun Pharmaceuticals, India, WHO HRP, PT. Tunggal Idaman Abdi
Development Stage: SRA/WHO PQ Approved
Development Phase: Limited Market Availability
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: DKT International, PT Harsen
Development Stage: Marketed
Development Phase: Limited Market Availability
Alternative Name: K4K20S4
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other, Other
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral, Subdermal
Developer: University of Edinburgh
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: DVD2
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal, Other
Developer: FHI 360
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: DMAU
User: Male
Hormonal: Yes
Duration Type: Short-acting
Developer: BIOQUAL, Inc., NICHD, University of California at Los Angeles
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Depot Medroxyprogesterone Acetate (DMPA) + Testosterone
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable, Subdermal
Developer: ANZAC Research Institute
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: National Research Institute for Family Planning in Beijing
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Plasma Membrane Calcium ATPase (PMCA) Inhibitors
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal Gel, Vaginal, Other
Developer: University of Manchester, Max Planck Institute
Development Phase: Discovery and Early Development
Alternative Name: Dapivirine (DPV) + levonorgestrel (LNG) vaginal ring
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: International Partnership for Microbicides, USAID
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development

Pages

Displaying 41 - 50 of 70
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Merck
Development Stage: Prototype Development
Alternative Name: Metalloprotease
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University
Development Stage: Target Validation
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Microchips Biotech, Inc.
Development Stage: Prototype Development
Target
User: Male
Hormonal: No
Developer: University of Kansas Medical Center, University of Minnesota
Development Stage: Target Validation
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Washington University
Development Stage: Compound ID/Selection
Alternative Name: Lavax Vaginal Suppository
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other
Developer: Lavax
Development Stage: Lead Optimization
User: Male
Hormonal: No
Delivery Method: Oral
Developer: North Shore University Hospital in New York
Development Stage: Lead Optimization
Alternative Name: Nomegestrol acetate (NOMAC) vaginal ring
User: Female
Hormonal: Yes
Delivery Method: Vaginal Ring
Developer: Merck
Development Stage: Prototype Development
User: Female, Male
Duration Type: Short-acting, Pericoital
Delivery Method: Injectable, Vaginal, Other, Other
Development Stage: Lead Optimization
User: Male
Hormonal: Yes
Developer: University of Kansas Medical Center, University of Minnesota
Development Stage: Lead Optimization

Pages

Displaying 21 - 30 of 121
Alternative Name: DVD2
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Vaginal, Other
Developer: FHI 360
Development Stage: Phase I
Alternative Name: DMAU
User: Male
Hormonal: Yes
Duration Type: Short-acting
Developer: BIOQUAL, Inc., NICHD, University of California at Los Angeles
Development Stage: Phase I
Alternative Name: Depot Medroxyprogesterone Acetate (DMPA) + Testosterone
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable, Subdermal
Developer: ANZAC Research Institute
Development Stage: Phase I
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: National Research Institute for Family Planning in Beijing
Alternative Name: Dapivirine (DPV) + levonorgestrel (LNG) vaginal ring
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: International Partnership for Microbicides, USAID
Development Stage: Phase I
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier, Vaginal Gel
Developer: ReProtect Inc.
Development Stage: Phase II
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: Bayer HealthCare
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Emergency
Delivery Method: Vaginal Gel, Vaginal, Other
Developer: Viramal Limited
Development Stage: Pre-clinical
Alternative Name: Merck Vaginal Ring MK-8342B
User: Female
Hormonal: Yes
Delivery Method: Vaginal Ring
Developer: Merck
Development Stage: Phase III
Alternative Name: Casea S
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Subdermal
Developer: GeSea Biosciences, FHI 360
Development Stage: Phase I

Pages

Displaying 31 - 40 of 52
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Innova Quality S.A.S
Development Stage: Marketed
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Allergan
Development Stage: Regulatory
Alternative Name: Woman's Condom (WC)
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Shanghai Dahua Medical Apparatus Co., Ltd, PATH
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: Regulatory
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Helm Pharmaceuticals, Fresenius Kabi
Development Stage: Marketed
Alternative Name: Amphora® Gel, lactic acid, citric acid, and potassium bitartrate
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Evofem Biosciences, Inc.
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Tianjin Condombao Medical Polyurethane Tech. Co. Ltd
Development Stage: SRA/WHO PQ Approved
Alternative Name: Pregna PPIUD T Cu 380A
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Pregna International Limited
Development Stage: SRA/WHO PQ Approved
Alternative Name: Progestin Vaginal Ring (PVR)
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Population Council, Grunenthal
Development Stage: Marketed
Alternative Name: VA w.o.w.
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: HLL Lifecare Limited, IXu LLC
Development Stage: SRA/WHO PQ Approved

Pages

CSV